Anzeige
Mehr »
Login
Samstag, 27.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
223 Leser
Artikel bewerten:
(0)

EQT Acquires Clinical Innovations, LLC

EQT acquires Clinical Innovations, the leading global, pure-play provider of single-use clinician-preferred medical devices for Labor & Delivery departments within hospitals

EQT to continue accelerating Clinical Innovations' growth by leveraging EQT's experience in scaling medical device businesses, through further investment in bringing the leading products to international markets, and by continuing to add new clinician-preferred products to the portfolio

PR Newswire

STOCKHOLM, Oct. 18, 2017 /PRNewswire/ --

The EQT Mid Market US fund ("EQT Mid Market US") today announced that it has acquired a majority stake in Clinical Innovations (the "Company"). Clinical Innovations is the leading global, pure-play provider of single-use clinician-preferred medical devices for Labor & Delivery ("L&D") departments within hospitals. The Company has recently expanded its product portfolio to also serve the Neonatal Intensive Care Unit ("NICU").

Clinical Innovations, founded in 1993 and headquartered in Salt Lake City, Utah, is the largest medical device company exclusively focused on L&D. Already a market leader in several categories with products such as the KiwiVacuum-Assisted Delivery System and KoalaIntrauterine Pressure Catheter, Clinical Innovations is developing state-of-the-art technologies and innovative medical devices that fulfill its mission of improving the lives of mothers and babies. The Company's manufacturing facility in Utah is ISO 13485 certified. Clinical Innovations has built the industry's largest specialized L&D-focused sales force and has developed strong relationships with specialty medical device distributors. The Company has approximately 165 full time employees and serves more than 80 countries globally.

Brendan Scollans, Partner at EQT Partners Inc. and Investment Advisor to EQT Mid Market US, said: "We look forward to supporting Clinical Innovations' CEO Ken Reali and his team through their next phase of growth. The Company's portfolio of innovative and high-growth new products, combined with an impressive global sales organization, has enabled it to become a market leader within L&D. EQT's healthcare expertise and global presence will help the Company continue accelerating its international expansion and the broadening of its of best-in-class L&D and NICU product set through acquisitions."

Jerry He, Partner at EQT Partners Asia Limited stated: "We are impressed by Clinical Innovations' success in the fields of L&D and Neonatal care. Its product portfolio offers unique value to doctors, mothers and babies around the world. We are committed to supporting the Company's international growth strategy, especially as it looks to bring the strong product lineup to China and other Asian markets."

"We are eager to partner with EQT as we continue to develop our L&D and NICU strategy that we have executed over the past several years" said Ken Reali, President and CEO of Clinical Innovations. "EQT is an ideal fit for Clinical Innovations and our continuing growth. EQT's relationships, global presence and philosophy fit well with the Company culture and our strong commitment to delivering excellent products to clinicians to care for mothers and their babies", Reali added.

Simpson Thacher & Bartlett LLP is serving as legal advisor to EQT Mid Market US. Moelis & Company and Cain Brothers served as financial advisors to Clinical Innovations.

Contacts:

Brendan Scollans,
Partner at EQT Partners,
Investment Advisor to EQT Mid Market US,
+1-(917)-281-0849

KEKST:
+ 1-(212)-521-4800 (US media)

Daniel Yunger,
daniel.yunger@kekst.com
EQT Press Office,
+46-8-506-55-334

About EQT

EQT is a leading alternative investments firm with approximately EUR 37 billion in raised capital across 24 funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 19 billion and approximately 110,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. EQT is an active investor and owner in the healthcare sector, including recent investments in Certara, Press Ganey, Ottobock, Sivantos, and Lima Corporate.

More info:www.eqtpartners.com

About Clinical Innovations

Clinical Innovations is one of the largest medical device companies exclusively focused on labor and delivery and the neonatal intensive care unit. The company is already a market leader in several categories with products such as the KoalaIntrauterine Pressure Catheter; KiwiVacuum-Assisted Delivery System; ROM PlusRupture of Membranes Test; traxi Panniculus Retractor; ClearView Uterine Manipulator; babyLance Safety Heelstick; and the recently added ebb Complete Tamponade System.Clinical Innovations is expanding its global presence while developing state-of-the-art technologies and innovative medical devices that fulfill its mission of improving the lives of mothers and their babies throughout the world.

More info: www.clinicalinnovations.com

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/eqt-ab/r/eqt-acquires-clinical-innovations--llc,c2370407

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.